Caitong International Asset Management Co. Ltd Takes $405,000 Position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Key Points

• Caitong International Asset Management Co. Ltd has acquired a stake in Tonix Pharmaceuticals, purchasing 22,662 shares valued at approximately $405,000, representing about 0.35% ownership of the company.
• Tonix Pharmaceuticals reported a significant loss in its recent quarterly earnings, with an EPS of ($3.86) against a consensus estimate of ($3.10), and a negative net margin of 828.22%.
• Institutional investors currently hold 82.26% of Tonix Pharmaceuticals' stock, with multiple hedge funds actively increasing their positions in the company.

Caitong International Asset Management Co. Ltd acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 22,662 shares of the company's stock, valued at approximately $405,000. Caitong International Asset Management Co. Ltd owned about 0.35% of Tonix Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in TNXP. Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals during the fourth quarter worth about $66,000. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals during the fourth quarter worth about $162,000. IFP Advisors Inc purchased a new position in Tonix Pharmaceuticals during the first quarter worth about $179,000. Rhumbline Advisers purchased a new position in Tonix Pharmaceuticals during the first quarter worth about $244,000. Finally, Point72 Asset Management L.P. purchased a new position in Tonix Pharmaceuticals during the fourth quarter worth about $526,000. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $59.76 on Wednesday. The firm has a market cap of $439.83 million, a price-to-earnings ratio of -1.51 and a beta of 1.70. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $6.76 and a 52 week high of $130.00. The firm's 50-day simple moving average is $40.29 and its two-hundred day simple moving average is $26.95.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.10) by ($0.76). Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 61.97%. The business had revenue of $2.00 million during the quarter, compared to the consensus estimate of $2.60 million. Analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Analysts Set New Price Targets

TNXP has been the topic of several analyst reports. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Wall Street Zen raised shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th.

Insider Activity

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 4,000 shares of the stock in a transaction dated Thursday, May 15th. The shares were bought at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the transaction, the chief executive officer directly owned 4,005 shares in the company, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.03% of the stock is currently owned by company insiders.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.